tetano
Editor, Senior Moderator
Pediatric Infectious Disease Journal:
January 2015 - Volume 34 - Issue 1 - p 73-78
doi: 10.1097/INF.0000000000000465
Vaccine Reports
[h=2]Dissecting the Immune Response to MF59-adjuvanted and Nonadjuvanted Seasonal Influenza Vaccines in Children Less Than Three Years of Age[/h] [h=3][/h] Zedda, Luisanna PhD[SUP]*[/SUP]; Forleo-Neto, Eduardo MD[SUP]*[/SUP]; Vertruyen, Andr? MD[SUP]?[/SUP]; Raes, Marc MD[SUP]?[/SUP]; Marchant, Arnaud MD, PhD[SUP]??[/SUP]; Jansen, Wim MSc[SUP]*[/SUP]; Clouting, Heather MSc[SUP]*[/SUP]; Arora, Ashwani MD[SUP]*[/SUP]; Beatty, Mark E. MD[SUP]*[/SUP]; Galli, Grazia PhD[SUP]*[/SUP]; Del Giudice, Giuseppe MD, PhD[SUP]*[/SUP]; Castellino, Flora MD[SUP]*[/SUP]
Free Access
Supplemental Author Material
Article Outline
[h=4]Author Information[/h]
From the [SUP]*[/SUP]Novartis Vaccines, Siena, Italy and Cambridge, MA; [SUP]?[/SUP]Sint Vincentius Ziekenhuis, Antwerp, Belgium; [SUP]?[/SUP]Kinderartsenassociatie, Hasselt, Belgium; [SUP]?[/SUP]ImmuneHealth, Charleroi, Belgium; and [SUP]?[/SUP]Institute for Medical Immunology, Universit? Libre de Bruxelles, Charleroi, Belgium.
Accepted for publication May 19, 2014.
This study was registered at www.clinicaltrials.gov [NCT01342796].
The study was supported by Novartis Vaccines. There is no conflict of interest related to this study.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal?s website ( www.pidj.com).
Address for correspondence: Giuseppe Del Giudice, MD, PhD, Novartis Vaccines, Via Fiorentina 1, Siena 53100, Italy. E-mail: giuseppe.del_giudice@novartis.com.
[h=4]Abstract[/h]
Introduction:
Annual seasonal influenza epidemics are particularly dangerous for the very young, the elderly and chronically ill individuals, in whom infection can cause severe morbidity, hospitalization and death. Existing, nonadjuvanted influenza vaccines exhibit a suboptimal immunogenicity and efficacy in immunologically naive subjects such as young children.
Methods:
This phase II, randomized clinical trial was conducted to evaluate the antibody and cell-mediated responses to a trivalent influenza vaccine administered without adjuvant (TIV) or adjuvanted with MF59 (ATIV) in previously nonvaccinated children less than 3 years of age.
Results:
The MF59-adjuvanted vaccine was well tolerated, and induced higher titers of hemagglutination inhibition antibodies able to recognize strains different from the one used in the vaccine (heterovariant) than TIV. The presence of the adjuvant MF59 induced a larger expansion of vaccine-specific CD4[SUP]+[/SUP] T cells. Interestingly, the adjuvant MF59 did not modify the cytokine profile of the elicited T cells, characterized by the production of IL-2 and TNF-α, and did not bias the response toward either Th1 or Th2. The advantage of ATIV over TIV was more pronounced for the virus strains that had not circulated in the years that preceded this study and for the heterovariant strains.
Conclusion:
These data highlight the relevant role played by the oil-in-water adjuvant MF59 in enhancing the immunogenicity of inactivated influenza vaccines in immunologically naive individuals.
http://journals.lww.com/pidj/Fullte...he_Immune_Response_to_MF59_adjuvanted.15.aspx
January 2015 - Volume 34 - Issue 1 - p 73-78
doi: 10.1097/INF.0000000000000465
Vaccine Reports
[h=2]Dissecting the Immune Response to MF59-adjuvanted and Nonadjuvanted Seasonal Influenza Vaccines in Children Less Than Three Years of Age[/h] [h=3][/h] Zedda, Luisanna PhD[SUP]*[/SUP]; Forleo-Neto, Eduardo MD[SUP]*[/SUP]; Vertruyen, Andr? MD[SUP]?[/SUP]; Raes, Marc MD[SUP]?[/SUP]; Marchant, Arnaud MD, PhD[SUP]??[/SUP]; Jansen, Wim MSc[SUP]*[/SUP]; Clouting, Heather MSc[SUP]*[/SUP]; Arora, Ashwani MD[SUP]*[/SUP]; Beatty, Mark E. MD[SUP]*[/SUP]; Galli, Grazia PhD[SUP]*[/SUP]; Del Giudice, Giuseppe MD, PhD[SUP]*[/SUP]; Castellino, Flora MD[SUP]*[/SUP]
Free Access
Supplemental Author Material
Article Outline
From the [SUP]*[/SUP]Novartis Vaccines, Siena, Italy and Cambridge, MA; [SUP]?[/SUP]Sint Vincentius Ziekenhuis, Antwerp, Belgium; [SUP]?[/SUP]Kinderartsenassociatie, Hasselt, Belgium; [SUP]?[/SUP]ImmuneHealth, Charleroi, Belgium; and [SUP]?[/SUP]Institute for Medical Immunology, Universit? Libre de Bruxelles, Charleroi, Belgium.
Accepted for publication May 19, 2014.
This study was registered at www.clinicaltrials.gov [NCT01342796].
The study was supported by Novartis Vaccines. There is no conflict of interest related to this study.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal?s website ( www.pidj.com).
Address for correspondence: Giuseppe Del Giudice, MD, PhD, Novartis Vaccines, Via Fiorentina 1, Siena 53100, Italy. E-mail: giuseppe.del_giudice@novartis.com.
Introduction:
Annual seasonal influenza epidemics are particularly dangerous for the very young, the elderly and chronically ill individuals, in whom infection can cause severe morbidity, hospitalization and death. Existing, nonadjuvanted influenza vaccines exhibit a suboptimal immunogenicity and efficacy in immunologically naive subjects such as young children.
Methods:
This phase II, randomized clinical trial was conducted to evaluate the antibody and cell-mediated responses to a trivalent influenza vaccine administered without adjuvant (TIV) or adjuvanted with MF59 (ATIV) in previously nonvaccinated children less than 3 years of age.
Results:
The MF59-adjuvanted vaccine was well tolerated, and induced higher titers of hemagglutination inhibition antibodies able to recognize strains different from the one used in the vaccine (heterovariant) than TIV. The presence of the adjuvant MF59 induced a larger expansion of vaccine-specific CD4[SUP]+[/SUP] T cells. Interestingly, the adjuvant MF59 did not modify the cytokine profile of the elicited T cells, characterized by the production of IL-2 and TNF-α, and did not bias the response toward either Th1 or Th2. The advantage of ATIV over TIV was more pronounced for the virus strains that had not circulated in the years that preceded this study and for the heterovariant strains.
Conclusion:
These data highlight the relevant role played by the oil-in-water adjuvant MF59 in enhancing the immunogenicity of inactivated influenza vaccines in immunologically naive individuals.
http://journals.lww.com/pidj/Fullte...he_Immune_Response_to_MF59_adjuvanted.15.aspx